Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Matthew J. Irby"'
Autor:
Martin Pacesa, Chun-Han Lin, Antoine Cléry, Aakash Saha, Pablo R. Arantes, Katja Bargsten, Matthew J. Irby, Frédéric H.T. Allain, Giulia Palermo, Peter Cameron, Paul D. Donohoue, Martin Jinek
Publikováno v:
Cell, 185 (22)
The target DNA specificity of the CRISPR-associated genome editor nuclease Cas9 is determined by complementarity to a 20-nucleotide segment in its guide RNA. However, Cas9 can bind and cleave partially complementary off-target sequences, which raises
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e6f5197b9f59bc39d96e7674a92678d
Autor:
Peter Cameron, Mckenzi S. Toh, Steven B. Kanner, John van der Oost, Scott Gradia, Bastien Vidal, Carolyn Williams, Samuel H. Sternberg, Lynda M. Banh, Alexandra M. Lied, Paul Daniel Donohoue, David B. Nyer, Chris R. Fuller, B. Kohrs, Mary M. Coons, Matthew J. Irby, Chun Han Lin, Leslie S. Edwards, Arthur L.G. Owen, Tim Künne, Tomer Rotstein, Sanne E. Klompe, Rachel Kennedy, Euan M. Slorach, Andrew May, Stan J. J. Brouns, Stephen C. Smith
Publikováno v:
Nature Biotechnology
Nature Biotechnology, 37, 1471-1477
Nature Biotechnology 37 (2019)
Nature Biotechnology, 37, 1471-1477
Nature Biotechnology 37 (2019)
Type I CRISPR–Cas systems are the most abundant adaptive immune systems in bacteria and archaea1,2. Target interference relies on a multi-subunit, RNA-guided complex called Cascade3,4, which recruits a trans-acting helicase-nuclease, Cas3, for targ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bca5f5a349524ce734ff58581aea866d
https://doi.org/10.1038/s41587-019-0310-0
https://doi.org/10.1038/s41587-019-0310-0
Autor:
David B. Nyer, Lynda M. Banh, Megan van Overbeek, Tomer Rotstein, Elaine Lau, Kevin Baek, Chris R. Fuller, Martin Pacesa, Euan M. Slorach, Andrew May, Martin Jinek, Mckenzi S. Toh, B. Kohrs, Jason Gibson, Bastien Vidal, Matthew J. Irby, Arthur L.G. Owen, Paul Daniel Donohoue, Peter Cameron
Publikováno v:
Molecular Cell. 81:3637-3649.e5
Summary The off-target activity of the CRISPR-associated nuclease Cas9 is a potential concern for therapeutic genome editing applications. Although high-fidelity Cas9 variants have been engineered, they exhibit varying efficiencies and have residual
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ccc48278c5abd0ee17e53467237d531
https://doi.org/10.1016/j.molcel.2021.07.035
https://doi.org/10.1016/j.molcel.2021.07.035